NasdaqGM - Nasdaq Real Time Price USD

Vaxxinity, Inc. (VAXX)

0.4601 -0.0047 (-1.01%)
As of 2:07 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Louis Garfield Reese IV Co-Founder & Executive Chairman of the Board 83.28k -- 1982
Ms. Mei Mei Hu J.D. CEO & Director 551.73k -- 1983
Mr. Jason Pesile CPA, M.B.A. Chief Accounting Officer -- -- 1973
Dr. Jean-Cosme Dodart Ph.D. Chief Scientific Officer -- -- --
Ms. Sumita Ray J.D. Chief Legal & Administrative Officer -- -- 1974
Mr. Jon Harrison Chief Government Officer -- -- --
Mr. Mark Joinnides MSE Chief of Staff -- -- --
Ms. Amy B. Fix M.B.A., M.S., R.A.C. Head of Regulatory -- -- --

Vaxxinity, Inc.

505 Odyssey Way
Merritt Island, FL 32953
United States
254 244 5739 https://www.vaxxinity.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
57

Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

Corporate Governance

Vaxxinity, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 10; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Vaxxinity, Inc. Earnings Call

Related Tickers

ABOS Acumen Pharmaceuticals, Inc.
3.1300
-0.94%
 
PRTA Prothena Corporation plc
20.94
+1.80%
 
ONCO Onconetix, Inc.
0.1265
-2.24%
 
ALLK Allakos Inc.
1.0200
-3.77%
 
HOOK HOOKIPA Pharma Inc.
0.7499
-1.96%
 
ASLN ASLAN Pharmaceuticals Limited
0.5398
-0.04%
 
HCWB HCW Biologics Inc.
1.5200
-8.43%
 
MBIO Mustang Bio, Inc.
0.3528
-4.81%
 
TENX Tenax Therapeutics, Inc.
3.6250
-1.76%
 
AZTR Azitra, Inc.
0.1950
+2.79%